Prof George Sledge presents data data from the MONARCH 2 trial during a press conference at the 2019 ESMO congress.
The MONARCH 2 trial looked at the CDK4/6 inhibitor abemaciclib plus fulvestrant in pre-, and peri- and postmenopausal breast cancer patients.
Watch Prof Sledge's interview with ecancer here.
Watch Prof Nadia Harbeck's comment here.
Read more about the study here.